

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>White Jonathan</u>			2. Issuer Name and Ticker or Trading Symbol <u>HAEMONETICS CORP [ HAE ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Science and Technology</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>07/24/2013</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
<u>400 WOOD ROAD</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>BRAINTREE MA 02184</u>								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				
<u>Common Stock</u>									<u>24,742</u>	<u>D</u>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
<u>Performance Shares</u>	<u>\$0.0</u>	<u>07/24/2013</u>		<u>A</u>		<u>25,000</u>		<u>03/31/2017<sup>(1)</sup></u>	<u>12/31/2017<sup>(1)</sup></u>	<u>Common Stock</u>	<u>25,000</u>	<u>\$0.0</u>	<u>25,000</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>\$26.47</u>							<u>10/27/2010<sup>(2)</sup></u>	<u>10/27/2016</u>	<u>Common Stock</u>	<u>24,484</u>		<u>24,484</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>\$27.495</u>							<u>10/27/2011<sup>(2)</sup></u>	<u>10/27/2017</u>	<u>Common Stock</u>	<u>30,776</u>		<u>30,776</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>\$30.025</u>							<u>01/28/2010<sup>(2)</sup></u>	<u>01/28/2016</u>	<u>Common Stock</u>	<u>35,282</u>		<u>35,282</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>\$30.67</u>							<u>10/25/2012<sup>(2)</sup></u>	<u>10/25/2018</u>	<u>Common Stock</u>	<u>35,130</u>		<u>35,130</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>\$33.925</u>							<u>07/20/2012<sup>(2)</sup></u>	<u>07/20/2018</u>	<u>Common Stock</u>	<u>27,948</u>		<u>27,948</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>\$39.055</u>							<u>10/24/2013<sup>(2)</sup></u>	<u>10/24/2019</u>	<u>Common Stock</u>	<u>32,192</u>		<u>32,192</u>	<u>D</u>	

**Explanation of Responses:**

1. Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).

2. Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

By: Alexander Steddan For: 07/26/2013

Jonathan White

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**